Rigel Pharmaceuticals

IPO

Novel therapies to enhance patient lives

Public · South San Francisco, United States · Founded 1996 · $21.4M raised

Employees
51–200
Founded
1996
Business Model
B2B
Website
rigel.com
Total Funding
$21.4M
Last Round
$14.9M Venture RoundJan 1999
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel small-molecule drugs that significantly improve the lives of patients with hematologic disorders and cancer. Rigel's commercial products include TAVALISSE (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for relapsed or refractory acute myeloid leukemia with IDH1 mutations, and Gavreto (pralsetinib) for certain RET-altered non-small cell lung cancers. The company is headquartered in South San Francisco, California.

Summary

Rigel Pharmaceuticals is a Biotech company based in South San Francisco, United States, founded in 1996. It has raised $21.4M in total across 2 rounds, most recently a $14.9M Venture Round in Jan 1999.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Credit LineCredit LineOct 2019
$10.0M

Sign up to see all 6 events

Funding: Venture Round. Amounts, valuations, and investors where available.

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Rigel Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/rigel-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/rigel-pharmaceuticals" alt="Rigel Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>